---
document_datetime: 2025-11-23 08:00:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/riarify.html
document_name: riarify.html
version: success
processing_time: 0.109707
conversion_datetime: 2025-12-26 20:08:32.804853
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.)

[RSS](/en/individual-human-medicine.xml/65457)

##### Withdrawn

This medicine's authorisation has been withdrawn

beclometasone / formoterol

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.)](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 6 March 2025 the European Commission withdrew the marketing authorisation for Riarify (beclometasone / formoterol / glycopyrronium bromide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Chiesi Farmaceutici S.p.A., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Riarify was granted marketing authorisation in the EU on 23 April 2018 for the symptomatic treatment and reduction of exacerbations in adult patients with chronic obstructive pulmonary disease (COPD) with airflow limitation and who are at risk of exacerbations. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2022.

Riarify was only marketed in Ireland and was a duplicate of another medicine called Trimbow, which remains available to patients in the EU.

The European public assessment report (EPAR) for Riarify will be updated to indicate that the marketing authorisation is no longer valid.

Riarify : EPAR - Medicine overview

Reference Number: EMA/486960/2019

English (EN) (140.1 KB - PDF)

**First published:** 26/04/2018

**Last updated:** 18/03/2025

[View](/en/documents/overview/riarify-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-843)

български (BG) (216.04 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/bg/documents/overview/riarify-epar-medicine-overview_bg.pdf)

español (ES) (143.44 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/es/documents/overview/riarify-epar-medicine-overview_es.pdf)

čeština (CS) (173.42 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/cs/documents/overview/riarify-epar-medicine-overview_cs.pdf)

dansk (DA) (140.79 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/da/documents/overview/riarify-epar-medicine-overview_da.pdf)

Deutsch (DE) (142.9 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/de/documents/overview/riarify-epar-medicine-overview_de.pdf)

eesti keel (ET) (137.91 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/et/documents/overview/riarify-epar-medicine-overview_et.pdf)

ελληνικά (EL) (234.42 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/el/documents/overview/riarify-epar-medicine-overview_el.pdf)

français (FR) (144.73 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/fr/documents/overview/riarify-epar-medicine-overview_fr.pdf)

hrvatski (HR) (160.5 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/hr/documents/overview/riarify-epar-medicine-overview_hr.pdf)

italiano (IT) (142.93 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/it/documents/overview/riarify-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (184.9 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/lv/documents/overview/riarify-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (169.63 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/lt/documents/overview/riarify-epar-medicine-overview_lt.pdf)

magyar (HU) (158.83 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/hu/documents/overview/riarify-epar-medicine-overview_hu.pdf)

Malti (MT) (181.94 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/mt/documents/overview/riarify-epar-medicine-overview_mt.pdf)

Nederlands (NL) (142.2 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/nl/documents/overview/riarify-epar-medicine-overview_nl.pdf)

polski (PL) (171.82 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/pl/documents/overview/riarify-epar-medicine-overview_pl.pdf)

português (PT) (142.87 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/pt/documents/overview/riarify-epar-medicine-overview_pt.pdf)

română (RO) (182.1 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/ro/documents/overview/riarify-epar-medicine-overview_ro.pdf)

slovenčina (SK) (165.13 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/sk/documents/overview/riarify-epar-medicine-overview_sk.pdf)

slovenščina (SL) (158.31 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/sl/documents/overview/riarify-epar-medicine-overview_sl.pdf)

Suomi (FI) (141.52 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/fi/documents/overview/riarify-epar-medicine-overview_fi.pdf)

svenska (SV) (140.58 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/sv/documents/overview/riarify-epar-medicine-overview_sv.pdf)

Riarify : EPAR - Risk-management-plan summary

English (EN) (5.97 MB - PDF)

**First published:** 06/09/2019

**Last updated:** 18/03/2025

[View](/en/documents/rmp-summary/riarify-epar-risk-management-plan-summary_en.pdf)

## Product information

Riarify : EPAR - Product Information

English (EN) (1.54 MB - PDF)

**First published:** 26/04/2018

**Last updated:** 18/03/2025

[View](/en/documents/product-information/riarify-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-614)

български (BG) (1.47 MB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/bg/documents/product-information/riarify-epar-product-information_bg.pdf)

español (ES) (782.66 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/es/documents/product-information/riarify-epar-product-information_es.pdf)

čeština (CS) (911.42 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/cs/documents/product-information/riarify-epar-product-information_cs.pdf)

dansk (DA) (765.38 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/da/documents/product-information/riarify-epar-product-information_da.pdf)

Deutsch (DE) (767.63 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/de/documents/product-information/riarify-epar-product-information_de.pdf)

eesti keel (ET) (782.76 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/et/documents/product-information/riarify-epar-product-information_et.pdf)

ελληνικά (EL) (1.55 MB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/el/documents/product-information/riarify-epar-product-information_el.pdf)

français (FR) (797.98 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/fr/documents/product-information/riarify-epar-product-information_fr.pdf)

hrvatski (HR) (844.72 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/hr/documents/product-information/riarify-epar-product-information_hr.pdf)

íslenska (IS) (763.85 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/is/documents/product-information/riarify-epar-product-information_is.pdf)

italiano (IT) (769.6 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/it/documents/product-information/riarify-epar-product-information_it.pdf)

latviešu valoda (LV) (1.05 MB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/lv/documents/product-information/riarify-epar-product-information_lv.pdf)

lietuvių kalba (LT) (944.41 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/lt/documents/product-information/riarify-epar-product-information_lt.pdf)

magyar (HU) (799.14 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/hu/documents/product-information/riarify-epar-product-information_hu.pdf)

Malti (MT) (1.03 MB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/mt/documents/product-information/riarify-epar-product-information_mt.pdf)

Nederlands (NL) (753.93 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/nl/documents/product-information/riarify-epar-product-information_nl.pdf)

norsk (NO) (724.38 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/no/documents/product-information/riarify-epar-product-information_no.pdf)

polski (PL) (983.15 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/pl/documents/product-information/riarify-epar-product-information_pl.pdf)

português (PT) (761.25 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/pt/documents/product-information/riarify-epar-product-information_pt.pdf)

română (RO) (994.95 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/ro/documents/product-information/riarify-epar-product-information_ro.pdf)

slovenčina (SK) (835.01 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/sk/documents/product-information/riarify-epar-product-information_sk.pdf)

slovenščina (SL) (809.42 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/sl/documents/product-information/riarify-epar-product-information_sl.pdf)

Suomi (FI) (745.6 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/fi/documents/product-information/riarify-epar-product-information_fi.pdf)

svenska (SV) (722.95 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/sv/documents/product-information/riarify-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0034 04/11/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Riarify : EPAR - All Authorised presentations

English (EN) (71.08 KB - PDF)

**First published:** 26/04/2018

**Last updated:** 18/03/2025

[View](/en/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-925)

български (BG) (97.73 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/bg/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_bg.pdf)

español (ES) (61.94 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/es/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_es.pdf)

čeština (CS) (83.67 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/cs/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (60.07 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/da/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (59.39 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/de/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (65.18 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/et/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (93.86 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/el/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_el.pdf)

français (FR) (64.46 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/fr/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (80.99 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/hr/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (58.77 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/is/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_is.pdf)

italiano (IT) (61.11 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/it/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (87.98 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/lv/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (85.87 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/lt/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (81.34 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/hu/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (89.24 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/mt/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (59.75 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/nl/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (62.43 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/no/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_no.pdf)

polski (PL) (83.69 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/pl/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_pl.pdf)

português (PT) (58.76 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/pt/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_pt.pdf)

română (RO) (84.39 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/ro/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (81.31 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/sk/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (69.8 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/sl/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (59.84 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/fi/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (74.22 KB - PDF)

**First published:**

26/04/2018

**Last updated:**

18/03/2025

[View](/sv/documents/all-authorised-presentations/riarify-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.) Active substance

- formoterol fumarate dihydrate
- glycopyrronium
- beclometasone dipropionate

International non-proprietary name (INN) or common name

- beclometasone
- formoterol

Therapeutic area (MeSH) Pulmonary Disease, Chronic Obstructive Anatomical therapeutic chemical (ATC) code R03AL09

### Pharmacotherapeutic group

Drugs for obstructive airway diseases

### Therapeutic indication

Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/004836 Marketing authorisation holder

Chiesi Farmaceutici S.p.A.

Via Palermo 26/A

Opinion adopted 22/02/2018 Marketing authorisation issued 23/04/2018 Withdrawal of marketing authorisation 06/03/2025 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Riarify : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (258.71 KB - PDF)

**First published:** 06/09/2019

**Last updated:** 18/03/2025

[View](/en/documents/procedural-steps-after/riarify-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Riarify-H-C-4836 : EPAR - Assessment Report - Variation

English (EN) (3.49 MB - PDF)

**First published:** 06/09/2019

**Last updated:** 18/03/2025

[View](/en/documents/variation-report/riarify-h-c-4836-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Riarify

Adopted

Reference Number: EMA/CHMP/136909/2019

English (EN) (107.92 KB - PDF)

**First published:** 01/03/2019

**Last updated:** 18/03/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-riarify_en.pdf)

## Initial marketing authorisation documents

Riarify : EPAR - Public assessment report

Adopted

Reference Number: EMA/155339/2018

English (EN) (639.63 KB - PDF)

**First published:** 26/04/2018

**Last updated:** 18/03/2025

[View](/en/documents/assessment-report/riarify-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Riarify

Adopted

Reference Number: EMA/CHMP/109090/2018 Rev. 1

English (EN) (134.65 KB - PDF)

**First published:** 23/02/2018

**Last updated:** 18/03/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-riarify_en.pdf)

#### News on Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019) 01/03/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2018) 23/02/2018

**This page was last updated on** 18/03/2025

## Share this page

[Back to top](#main-content)